Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose abiraterone added to ADT plus radiotherapy for locally recurrent prostate cancer after prostatectomy
IRCT20120618010057N2Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of abiraterone in prostate cancer (PCa) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Biochemical free survival. Started Apr 2022; status: completed.
02
Drugs
abiraterone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on IRCT20120618010057N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120618010057N2.